EMERYVILLE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that the company has been certified as a Great Place to Work by the Great Place to Work® Institute. Gritstone earned this highly desirable credential based on a comprehensive set of ratings provided by its employees in an anonymous survey. The award is based entirely on what current employees say about their experience working at Gritstone bio.
“We are very proud to receive the designation as a Great Place to Work,” said Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone. “As a fully integrated vaccine discovery, development and manufacturing company, our employees span a variety of functions and worksites and to understand that they collectively find Gritstone a great place to work, which enabled this award, speaks to the depth of our mission and culture. We are committed to enabling our employees to contribute, grow, and flourish while on our journey to improve patient outcomes and eliminate disease.”
Great Place to Work® is the global authority on workplace culture, employee experience, and the leadership behaviors proven to deliver market-leading revenue, employee retention and increased innovation.
Stacy Proctor, Senior Vice President and Head of People of Gritstone, added, “Gritstone employees are amazing and passionate people who continually reinforce trust and camaraderie across the Gritstone organization. This recognition acknowledges the inclusive and rewarding work environment, culture, and pride of working at Gritstone.”
To learn more about Gritstone’s culture and job opportunities, visit https://gritstonebio.com/career-opportunities/
About Great Place to Work Certification™
Great Place to Work® Certification™ is the most definitive “employer-of-choice” recognition that companies aspire to achieve. It is the only recognition based entirely on what employees report about their workplace experience – specifically, how consistently they experience a high-trust workplace. Great Place to Work Certification is recognized worldwide by employees and employers alike and is the global benchmark for identifying and recognizing outstanding employee experience. Every year, more than 10,000 companies across 60 countries apply to get Great Place to Work-Certified.
Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology company that aims to create the world’s most potent vaccines. We leverage our innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with our collaborators, we are advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease. www.gritstonebio.com
Gritstone Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to the potential of Gritstone’s therapeutic programs; the advancements in the company’s ongoing clinical trials; the timing of data announcements related to ongoing clinical trials and the initiation of future clinical trials. Such forward-looking statements involve substantial risks and uncertainties that could cause Gritstone’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including Gritstone’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Gritstone’s ability to successfully establish, protect and defend its intellectual property and other matters that could affect the sufficiency of existing cash to fund operations. Gritstone undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see Gritstone’s most recent Quarterly Report on Form 10-Q filed on May 5, 2022 and any current and periodic reports filed with the Securities and Exchange Commission.
George E. MacDougall
Director, Investor Relations & Corp Comms
Gritstone bio, Inc.